On January 7, 2021 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 14th at 11:40 a.m. ET (Press release, CytomX Therapeutics, JAN 7, 2021, View Source [SID1234573626]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CytomX Therapeutics will also participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event taking place from January 11-14, 2021.

Webcast from the conference and corporate access event will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. An archived replay of the conference presentation will be available for 90 days following the conference. A recording of the corporate access presentation will also be available for 30 days following the event.